All terms in NCIT
| Label | Id | Description |
|---|---|---|
| Mycosis Fungoides and Sezary Syndrome N2a TNM Finding v7 | NCIT_C88242 | [Clone negative. Note: A T-cell clone is defined by PCR or Southern blot analysis of the T-cell receptor gene. (from AJCC 7th Ed.)] |
| Mycosis Fungoides and Sezary Syndrome N2 TNM Finding v7 | NCIT_C88241 | [Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. Note: Dutch grade 2: dermatopathic lymphadenopathy; early involvement by mycosis fungoides (presence of cerebriform nuclei greater than 7.5 micrometers). NCI LN3: aggregates of atypical lymphocytes; nodal architecture preserved. (from AJCC 7th Ed.)] |
| Mycosis Fungoides and Sezary Syndrome N2b TNM Finding v7 | NCIT_C88243 | [Clone positive. Note: A T-cell clone is defined by PCR or Southern blot analysis of the T-cell receptor gene. (from AJCC 7th Ed.)] |
| Mycosis Fungoides and Sezary Syndrome N3 TNM Finding v7 | NCIT_C88244 | [Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone positive or negative. Note: Dutch grade 3: partial effacement of lymph node architecture; many atypical cerebriform mononuclear cells (CMCs). Dutch grade 4: complete effacement of lymph node. NCI LN4: partial/complete effacement of nodal architecture by atypical lymphocytes or frankly neoplastic cells. (from AJCC 7th Ed.)] |
| Mycosis Fungoides and Sezary Syndrome NX TNM Finding v7 | NCIT_C88245 | [Clinically abnormal peripheral lymph nodes; no histologic confirmation. (from AJCC 7th Ed.)] |
| Mycosis Fungoides and Sezary Syndrome N1b TNM Finding v7 | NCIT_C88240 | [Clone positive. Note: A T-cell clone is defined by PCR or Southern blot analysis of the T-cell receptor gene. (from AJCC 7th Ed.)] |
| Primary Cutaneous Lymphoma TNM Finding v7 | NCIT_C88228 | [A finding about one or more characteristics of primary cutaneous lymphoma, following the rules of the TNM v7 classification system. Mycosis fungoides and Sezary syndrome have a formal staging system proposed by the International Society for Cutaneous Lymphomas (ISCL) and EORTC. The other cutaneous non-Hodgkin lymphomas are staged using the same system for lymphomas presenting in other anatomic locations. (from AJCC 7th Ed.)] |
| Serum Cystatin C Assay | NCIT_C88224 | [An immunoassay used for the measurement of cystatin-C levels in the serum to determine the glomerular filtration rate.] |
| Urinary Creatinine Assay | NCIT_C88225 | [A laboratory test used for the measurement of creatinine levels in the urine to determine the degree of renal dysfunction.] |
| Creatinine Measurement | NCIT_C64547 | [A quantitative measurement of the amount of creatinine present in a sample.] |
| Urinary Microalbumin Assay | NCIT_C88226 | [An immunoassay used for the measurement of microalbumin levels in the urine to determine the glomerular filtration rate.] |
| Serum Creatinine Assay | NCIT_C88227 | [A laboratory test used for the measurement of creatinine levels in the serum to determine the glomerular filtration rate.] |
| Mycosis Fungoides and Sezary Syndrome TX TNM Finding v7 | NCIT_C88231 | [Primary tumor cannot be assessed. (from AJCC 7th Ed.)] |
| Mycosis Fungoides and Sezary Syndrome T1 TNM Finding v7 | NCIT_C88232 | [Limited patches, papules, and/or plaques covering less than 10% of the skin surface. May further stratify into T1a (patch only) vs. T1b (plaque +/- patch). Note: for skin, patch indicates any size skin lesion without significant elevation or induration. Presence/absence of hypo- or hyperpigmentation, scale, crusting, and/or poikiloderma should be noted. Plaque indicates any size skin lesion that is elevated or indurated. Presence or absence of scale, crusting, and/or poikiloderma should be noted. Histologic features such as folliculotropism or large-cell transformation (more than 25% large cells), CD30+ or CD30-, and clinical features such as ulceration are important to document. (from AJCC 7th Ed.)] |
| Mycosis Fungoides and Sezary Syndrome T2 TNM Finding v7 | NCIT_C88233 | [Patches, papules, or plaques covering 10% or more of the skin surface. May further stratify into T2a (patch only) vs. T2b (plaque +/- patch). (from AJCC 7th Ed.)] |
| Mycosis Fungoides and Sezary Syndrome T3 TNM Finding v7 | NCIT_C88234 | [One or more tumors (equal or greater than 1 cm diameter). Note: for skin, tumor indicates at least 1 cm diameter solid or nodular lesion with evidence of depth and/or vertical growth. Note total number of lesions, total volume of lesions, largest size lesion, and region of body involved. Also note if histologic evidence of large-cell transformation has occurred. Phenotyping for CD30 is encouraged. (from AJCC 7th Ed.)] |
| Vulvar Soft Tissue Neoplasm | NCIT_C40316 | [A benign or malignant mesenchymal neoplasm of the vulva. Representative examples include leiomyoma, cellular angiofibroma, angiomyxoma, leiomyosarcoma, liposarcoma, and childhood botryoid-type embryonal rhabdomyosarcoma.] |
| VFQ25-Interviewer Administered Format - Often Irritable Because of Eyesight | NCIT_C112769 | [Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Well-Being or Distress: I am often irritable because of my eyesight.] |
| Vulvar Sarcoma | NCIT_C40317 | [A malignant mesenchymal neoplasm that arises from the vulva. Representative examples include childhood botryoid-type embryonal rhabdomyosarcoma, alveolar soft part sarcoma, and leiomyosarcoma.] |
| Malignant Vulvar Neoplasm | NCIT_C7502 | [A primary or metastatic malignant neoplasm involving the vulva.] |